178 related articles for article (PubMed ID: 18555674)
1. Liposomal vasoactive intestinal peptide for lung application: protection from proteolytic degradation.
Stark B; Andreae F; Mosgoeller W; Edetsberger M; Gaubitzer E; Koehler G; Prassl R
Eur J Pharm Biopharm; 2008 Sep; 70(1):153-64. PubMed ID: 18555674
[TBL] [Abstract][Full Text] [Related]
2. Depot formulation of vasoactive intestinal peptide by protamine-based biodegradable nanoparticles.
Wernig K; Griesbacher M; Andreae F; Hajos F; Wagner J; Mosgoeller W; Zimmer A
J Control Release; 2008 Sep; 130(2):192-8. PubMed ID: 18601963
[TBL] [Abstract][Full Text] [Related]
3. Inhalable liposomal formulation for vasoactive intestinal peptide.
Hajos F; Stark B; Hensler S; Prassl R; Mosgoeller W
Int J Pharm; 2008 Jun; 357(1-2):286-94. PubMed ID: 18328650
[TBL] [Abstract][Full Text] [Related]
4. Association of vasoactive intestinal peptide with polymer-grafted liposomes: structural aspects for pulmonary delivery.
Stark B; Debbage P; Andreae F; Mosgoeller W; Prassl R
Biochim Biophys Acta; 2007 Mar; 1768(3):705-14. PubMed ID: 17204237
[TBL] [Abstract][Full Text] [Related]
5. Formulation design and in vivo evaluation of dry powder inhalation system of new vasoactive intestinal peptide derivative ([R(15, 20, 21), L(17), A(24,25), des-N(28)]-VIP-GRR) in experimental asthma/COPD model rats.
Onoue S; Aoki Y; Matsui T; Kojo Y; Misaka S; Mizumoto T; Yamada S
Int J Pharm; 2011 May; 410(1-2):54-60. PubMed ID: 21419198
[TBL] [Abstract][Full Text] [Related]
6. Liposomal vasoactive intestinal peptide.
Sethi V; Onyüksel H; Rubinstein I
Methods Enzymol; 2005; 391():377-95. PubMed ID: 15721392
[TBL] [Abstract][Full Text] [Related]
7. Development of dry powder inhalation system of novel vasoactive intestinal peptide (VIP) analogue for pulmonary administration.
Ohmori Y; Onoue S; Endo K; Matsumoto A; Uchida S; Yamada S
Life Sci; 2006 Jun; 79(2):138-43. PubMed ID: 16458931
[TBL] [Abstract][Full Text] [Related]
8. Stabilization of vasoactive intestinal peptide by lipids.
Gololobov G; Noda Y; Sherman S; Rubinstein I; Baranowska-Kortylewicz J; Paul S
J Pharmacol Exp Ther; 1998 May; 285(2):753-8. PubMed ID: 9580623
[TBL] [Abstract][Full Text] [Related]
9. Inhalable powder formulation of a stabilized vasoactive intestinal peptide (VIP) derivative: anti-inflammatory effect in experimental asthmatic rats.
Misaka S; Aoki Y; Karaki S; Kuwahara A; Mizumoto T; Onoue S; Yamada S
Peptides; 2010 Jan; 31(1):72-8. PubMed ID: 19808073
[TBL] [Abstract][Full Text] [Related]
10. New formulation of vasoactive intestinal peptide using liposomes in hyaluronic acid gel for uveitis.
Lajavardi L; Camelo S; Agnely F; Luo W; Goldenberg B; Naud MC; Behar-Cohen F; de Kozak Y; Bochot A
J Control Release; 2009 Oct; 139(1):22-30. PubMed ID: 19481575
[TBL] [Abstract][Full Text] [Related]
11. Pharmacological effects and lung-binding characteristics of a novel VIP analogue, [R15, 20, 21, L17]-VIP-GRR (IK312532).
Ohmori Y; Maruyama S; Kimura R; Onoue S; Matsumoto A; Endo K; Iwanaga T; Kashimoto K; Yamada S
Regul Pept; 2004 Dec; 123(1-3):201-7. PubMed ID: 15518913
[TBL] [Abstract][Full Text] [Related]
12. Novel glycosylated VIP analogs: synthesis, biological activity, and metabolic stability.
Dangoor D; Biondi B; Gobbo M; Vachutinski Y; Fridkin M; Gozes I; Rocchi R
J Pept Sci; 2008 Mar; 14(3):321-8. PubMed ID: 17924396
[TBL] [Abstract][Full Text] [Related]
13. The vasoactive intestinal peptide receptor turnover in pulmonary arteries indicates an important role for VIP in the rat lung circulation.
Petkov V; Gentscheva T; Schamberger C; Haberl I; Artl A; Andreae F; Mosgoeller W
Ann N Y Acad Sci; 2006 Jul; 1070():481-3. PubMed ID: 16888213
[TBL] [Abstract][Full Text] [Related]
14. Bioactive analogues and drug delivery systems of vasoactive intestinal peptide (VIP) for the treatment of asthma/COPD.
Onoue S; Yamada S; Yajima T
Peptides; 2007 Sep; 28(9):1640-50. PubMed ID: 17537541
[TBL] [Abstract][Full Text] [Related]
15. Inhaled vasoactive intestinal peptide exerts immunoregulatory effects in sarcoidosis.
Prasse A; Zissel G; Lützen N; Schupp J; Schmiedlin R; Gonzalez-Rey E; Rensing-Ehl A; Bacher G; Cavalli V; Bevec D; Delgado M; Müller-Quernheim J
Am J Respir Crit Care Med; 2010 Aug; 182(4):540-8. PubMed ID: 20442436
[TBL] [Abstract][Full Text] [Related]
16. Glucose-targeted niosomes deliver vasoactive intestinal peptide (VIP) to the brain.
Dufes C; Gaillard F; Uchegbu IF; Schätzlein AG; Olivier JC; Muller JM
Int J Pharm; 2004 Nov; 285(1-2):77-85. PubMed ID: 15488681
[TBL] [Abstract][Full Text] [Related]
17. Chemical synthesis and formulation design of a PEGylated vasoactive intestinal peptide derivative with improved metabolic stability.
Onoue S; Matsui T; Kato M; Mizumoto T; Liu B; Liu L; Karaki S; Kuwahara A; Yamada S
Eur J Pharm Sci; 2013 Jun; 49(3):382-9. PubMed ID: 23608612
[TBL] [Abstract][Full Text] [Related]
18. Downregulation of endotoxin-induced uveitis by intravitreal injection of vasoactive intestinal Peptide encapsulated in liposomes.
Lajavardi L; Bochot A; Camelo S; Goldenberg B; Naud MC; Behar-Cohen F; Fattal E; de Kozak Y
Invest Ophthalmol Vis Sci; 2007 Jul; 48(7):3230-8. PubMed ID: 17591893
[TBL] [Abstract][Full Text] [Related]
19. Intratracheal and subcutaneous liposomal VIP normalizes arterial pressure in spontaneously hypertensive hamsters.
Rubinstein I; Ikezaki H; Onyüksel H
Int J Pharm; 2006 Jun; 316(1-2):144-7. PubMed ID: 16580160
[TBL] [Abstract][Full Text] [Related]
20. Effect of vasoactive intestinal peptide on pulmonary surfactants phospholipid synthesis in lung explants.
Li L; Luo ZQ; Zhou FW; Feng DD; Guang CX; Zhang CQ; Sun XH
Acta Pharmacol Sin; 2004 Dec; 25(12):1652-8. PubMed ID: 15569411
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
